MTX was also shown to inhibit the degradation of the NF-κB repressor IkB-α [3], and reduced levels of phosphorylated RelA (p65) were found among rheumatoid arthritis patients receiving low-dose MTX therapy [2]. The gene discussed is RELA; the disease is rheumatoid arthritis.